BrdU

GWB-3AD5A4

IIB5

Each vial contains 100 ?l 1 mg/ml purified antibody in PBS containing 0. 09% sodium azide. The immunocytochemical detection of bromodeoxyuridine (BrdU) incorporated into DNA is a powerful tool to study the cytokinetics of normal and neoplastic cells. In vitro or in vivo labeling of tumor cells with the thymidine analogue BrdU and the subsequent detection of incorporated BrdU with specific anti-BrdU monoclonal antibodies is an accurate and comprehensive method to quantitate the degree of DNA-synthesis. BrdU is incorporated into the newly synthezised DNA of the S-phase cells and can thus provide an estimate for the fraction of cells in S-phase. Also dynamic proliferative information (such as the S-phase transit rate and the potential doubling time) can be obtained. by means of bivariate BrdU/DNA flow cytometric analysis. N/A 1. Schutte. B. Reynders. M. M. van Assche. C. L. Hupperets. P. S. Bosman. F. T. and Blijham. G. H. (1987). An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry. Cytometry 8. 372-6. Tinnemans. M. M. Schutte. B. Lenders. M. H. Ten Velde. G. P. Ramaekers. F. C. and Blijham. G. H. (1993). Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling. Br J Cancer 67. 1217-22. van Engeland. M. Kuijpers. H. J. Ramaekers. F. C. Reutelingsperger. C. P. and Schutte. B. (1997). Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 235. 421-430.